Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells $4,698,225.00 in Stock

United Therapeutics Corporation (NASDAQ:UTHR) CEO Martine Rothblatt sold 9,500 shares of the business’s stock in a transaction that occurred on Monday, September 21st. The shares were sold at an average price of $494.55, for a total value of $4,698,225.00. Following the completion of the sale, the chief executive officer owned 324,443 shares of the company’s stock, valued at $160,453,285.65. The trade was a 2.84% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link.

United Therapeutics Stock Performance

UTHR traded up $4.49 during trading on Tuesday, hitting $497.59. 392,857 shares of the stock were exchanged, compared to its average volume of 516,339. The firm has a 50 day simple moving average of $514.63 and a 200 day simple moving average of $540.46. The firm has a market cap of $21.34 billion, a price-to-earnings ratio of 17.80, a P/E/G ratio of 2.48 and a beta of 0.56. United Therapeutics Corporation has a 1 year low of $409.07 and a 1 year high of $609.35.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share for the quarter, topping the consensus estimate of $6.86 by $0.41. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The business had revenue of $783.30 million during the quarter, compared to analysts’ expectations of $804.65 million. During the same period in the prior year, the business earned $6.41 EPS. The business’s revenue for the quarter was down 1.9% compared to the same quarter last year. As a group, equities analysts anticipate that United Therapeutics Corporation will post 26.21 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have commented on UTHR shares. Morgan Stanley set a $515.00 target price on shares of United Therapeutics in a research report on Thursday, August 6th. Bank of America dropped their price objective on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a research note on Friday, July 10th. JPMorgan Chase & Co. lifted their price objective on shares of United Therapeutics from $685.00 to $687.00 and gave the company an “overweight” rating in a report on Thursday, July 23rd. Royal Bank Of Canada reduced their price objective on shares of United Therapeutics from $704.00 to $677.00 and set an “outperform” rating for the company in a research note on Thursday, August 6th. Finally, Weiss Ratings lowered United Therapeutics from a “buy (b)” rating to a “buy (b-)” rating in a report on Thursday, August 27th. Eleven analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, United Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $646.00.

Institutional Trading of United Therapeutics

A number of institutional investors have recently modified their holdings of the company. Toth Financial Advisory Corp grew its position in shares of United Therapeutics by 2,400.0% in the 2nd quarter. Toth Financial Advisory Corp now owns 50 shares of the biotechnology company’s stock worth $27,000 after buying an additional 48 shares during the last quarter. Fiduciary Financial Advisors purchased a new stake in United Therapeutics during the second quarter valued at approximately $30,000. Caitlin John LLC purchased a new stake in United Therapeutics during the second quarter valued at approximately $37,000. International Assets Investment Management LLC boosted its stake in United Therapeutics by 426.7% in the first quarter. International Assets Investment Management LLC now owns 79 shares of the biotechnology company’s stock valued at $45,000 after acquiring an additional 64 shares in the last quarter. Finally, Cullen Frost Bankers Inc. grew its holdings in United Therapeutics by 3,333.3% in the fourth quarter. Cullen Frost Bankers Inc. now owns 103 shares of the biotechnology company’s stock worth $50,000 after purchasing an additional 100 shares during the last quarter. 94.08% of the stock is currently owned by institutional investors.

About United Therapeutics

United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for serious and life-threatening conditions, with a primary emphasis on pulmonary arterial hypertension (PAH). The company’s products are designed to improve pulmonary blood flow and reduce the effects of this progressive disease.

United Therapeutics’ PAH portfolio includes Remodulin (treprostinil) injection, Orenitram (treprostinil) extended-release tablets, and Tyvaso (treprostinil), which is available as an inhalation solution and as the Tyvaso DPI dry-powder inhaler.